Explorez tous les épisodes du podcast Cancer Connections

How does a discovery scientist become a two-time biotech founder?

In the inaugural episode of Cancer Connections, Parker Moss sits down with Dr Simon Boulton, a world-renowned scientist whose work in DNA damage repair and telomere maintenance has transformed our understanding of how cancer develops—and how we can better treat it.

Although a research scientist by training, Simon recognised the therapeutic potential of his discoveries and went on to co-found Artios Pharma and, more recently, launch ALTx Therapeutics, taking breakthrough research from the lab towards meaningful patient impact.

Together, they explore what motivates someone to take that leap from academia into entrepreneurship, the importance of the people you work with, learn from, and build alongside, and what it really takes to translate cutting-edge science into new medicines for patients.

Before the conversations begin, meet the voice behind Cancer Connections.

In this trailer episode, host Parker Moss shares the personal and professional journey that led him into cancer innovation. From a career in technology and venture capital to a deeply personal experience with childhood cancer, Parker reflects on the experiences that shaped his commitment to improving outcomes for patients with cancer.

He discusses the breakthroughs in cancer research that have him most excited, why collaboration across science, medicine, industry and investment is crucial to turning discoveries into patient benefit, and what he hopes to uncover through conversations with members of the Cancer Research Horizons Expert Network.

Because, as Parker says, “it really takes a village to bring a cancer drug to market.”

How does a preclinical UK biotech get acquired for up to $1.5 billion by one of pharma’s giants?

Parker Moss sits down with Jonathan Tobin, a science-driven investor that heads up the London office of Brandon Capital, to answer that very question. Jonathan takes us inside the scientific experiments, investment decisions, and strategic pivots that saw Myricx Bio transform from a small, single-asset biotech into a platform-based antibody-drug conjugate (ADC) pioneer, ultimately attracting the attention of Novartis.

Parker and Jonathan unpack the science behind Myricx Bio, from the biology of N-myristoyltransferase (NMT) to the fundamentals of the ADC trinity: antibody, payload, linker. They also look to the future of ADCs and explore where Jonathan believes the next breakthrough in cancer therapy will come from. Spoiler alert: it’s in vivo CAR-T.